Page 2,115«..1020..2,1142,1152,1162,117..2,1202,130..»

Category Archives: Transhuman News

Human genetics – Wikipedia

Posted: November 12, 2016 at 5:20 pm

Human Genetics is the study of inheritance as it occurs in human beings. Human genetics encompasses a variety of overlapping fields including: classical genetics, cytogenetics, molecular genetics, biochemical genetics, genomics, population genetics, developmental genetics, clinical genetics, and genetic counseling.

Genes can be the common factor of the qualities of most human-inherited traits. Study of human genetics can be useful as it can answer questions about human nature, understand the diseases and development of effective disease treatment, and understand genetics of human life. This article describes only basic features of human genetics; for the genetics of disorders please see: Medical genetics.

Inheritance of traits for humans are based upon Gregor Mendel's model of inheritance. Mendel deduced that inheritance depends upon discrete units of inheritance, called factors or genes.[1]

Autosomal traits are associated with a single gene on an autosome (non-sex chromosome)they are called "dominant" because a single copyinherited from either parentis enough to cause this trait to appear. This often means that one of the parents must also have the same trait, unless it has arisen due to an unlikely new mutation. Examples of autosomal dominant traits and disorders are Huntington's disease and achondroplasia.

Autosomal recessive traits is one pattern of inheritance for a trait, disease, or disorder to be passed on through families. For a recessive trait or disease to be displayed two copies of the trait or disorder needs to be presented. The trait or gene will be located on a non-sex chromosome. Because it takes two copies of a trait to display a trait, many people can unknowingly be carriers of a disease. From an evolutionary perspective, a recessive disease or trait can remain hidden for several generations before displaying the phenotype. Examples of autosomal recessive disorders are albinism, cystic fibrosis.

X-linked genes are found on the sex X chromosome. X-linked genes just like autosomal genes have both dominant and recessive types. Recessive X-linked disorders are rarely seen in females and usually only affect males. This is because males inherit their X chromosome and all X-linked genes will be inherited from the maternal side. Fathers only pass on their Y chromosome to their sons, so no X-linked traits will be inherited from father to son. Men cannot be carriers for recessive X linked traits, as they only have one X chromosome, so any X linked trait inherited from the mother will show up.

Females express X-linked disorders when they are homozygous for the disorder and become carriers when they are heterozygous. X-linked dominant inheritance will show the same phenotype as a heterozygote and homozygote. Just like X-linked inheritance, there will be a lack of male-to-male inheritance, which makes it distinguishable from autosomal traits. One example of an X-linked trait is CoffinLowry syndrome, which is caused by a mutation in ribosomal protein gene. This mutation results in skeletal, craniofacial abnormalities, mental retardation, and short stature.

X chromosomes in females undergo a process known as X inactivation. X inactivation is when one of the two X chromosomes in females is almost completely inactivated. It is important that this process occurs otherwise a woman would produce twice the amount of normal X chromosome proteins. The mechanism for X inactivation will occur during the embryonic stage. For people with disorders like trisomy X, where the genotype has three X chromosomes, X-inactivation will inactivate all X chromosomes until there is only one X chromosome active. Males with Klinefelter syndrome, who have an extra X chromosome, will also undergo X inactivation to have only one completely active X chromosome.

Y-linked inheritance occurs when a gene, trait, or disorder is transferred through the Y chromosome. Since Y chromosomes can only be found in males, Y linked traits are only passed on from father to son. The testis determining factor, which is located on the Y chromosome, determines the maleness of individuals. Besides the maleness inherited in the Y-chromosome there are no other found Y-linked characteristics.

A pedigree is a diagram showing the ancestral relationships and transmission of genetic traits over several generations in a family. Square symbols are almost always used to represent males, whilst circles are used for females. Pedigrees are used to help detect many different genetic diseases. A pedigree can also be used to help determine the chances for a parent to produce an offspring with a specific trait.

Four different traits can be identified by pedigree chart analysis: autosomal dominant, autosomal recessive, x-linked, or y-linked. Partial penetrance can be shown and calculated form pedigrees. Penetrance is the percentage expressed frequency with which individuals of a given genotype manifest at least some degree of a specific mutant phenotype associated with a trait.

Inbreeding, or mating between closely related organisms, can clearly be seen on pedigree charts. Pedigree charts of royal families often have a high degree of inbreeding, because it was customary and preferable for royalty to marry another member of royalty. Genetic counselors commonly use pedigrees to help couples determine if the parents will be able to produce healthy children.

A karyotype is a very useful tool in cytogenetics. A karyotype is picture of all the chromosomes in the metaphase stage arranged according to length and centromere position. A karyotype can also be useful in clinical genetics, due to its ability to diagnose genetic disorders. On a normal karyotype, aneuploidy can be detected by clearly being able to observe any missing or extra chromosomes.[1]

Giemsa banding, g-banding, of the karyotype can be used to detect deletions, insertions, duplications, inversions, and translocations. G-banding will stain the chromosomes with light and dark bands unique to each chromosome. A FISH, fluorescent in situ hybridization, can be used to observe deletions, insertions, and translocations. FISH uses fluorescent probes to bind to specific sequences of the chromosomes that will cause the chromosomes to fluoresce a unique color.[1]

Genomics refers to the field of genetics concerned with structural and functional studies of the genome.[1] A genome is all the DNA contained within an organism or a cell including nuclear and mitochondrial DNA. The human genome is the total collection of genes in a human being contained in the human chromosome, composed of over three billion nucleotides.[2] In April 2003, the Human Genome Project was able to sequence all the DNA in the human genome, and to discover that the human genome was composed of around 20,000 protein coding genes.

Medical genetics' is the branch of medicine that involves the diagnosis and management of hereditary disorders. Medical genetics is the application of genetics to medical care. It overlaps human genetics, for example, research on the causes and inheritance of genetic disorders would be considered within both human genetics and medical genetics, while the diagnosis, management, and counseling of individuals with genetic disorders would be considered part of medical genetics.

Population genetics is the branch of evolutionary biology responsible for investigating processes that cause changes in allele and genotype frequencies in populations based upon Mendelian inheritance.[3] Four different forces can influence the frequencies: natural selection, mutation, gene flow (migration), and genetic drift. A population can be defined as a group of interbreeding individuals and their offspring. For human genetics the populations will consist only of the human species. The Hardy-Weinberg principle is a widely used principle to determine allelic and genotype frequencies.

In addition to nuclear DNA, humans (like almost all eukaryotes) have mitochondrial DNA. Mitochondria, the "power houses" of a cell, have their own DNA. Mitochondria are inherited from one's mother, and its DNA is frequently used to trace maternal lines of descent (see mitochondrial Eve). Mitochondrial DNA is only 16kb in length and encodes for 62 genes.

The XY sex-determination system is the sex-determination system found in humans, most other mammals, some insects (Drosophila), and some plants (Ginkgo). In this system, the sex of an individual is determined by a pair of sex chromosomes (gonosomes). Females have two of the same kind of sex chromosome (XX), and are called the homogametic sex. Males have two distinct sex chromosomes (XY), and are called the heterogametic sex.

Sex linkage is the phenotypic expression of an allele related to the chromosomal sex of the individual. This mode of inheritance is in contrast to the inheritance of traits on autosomal chromosomes, where both sexes have the same probability of inheritance. Since humans have many more genes on the X than the Y, there are many more X-linked traits than Y-linked traits. However, females carry two or more copies of the X chromosome, resulting in a potentially toxic dose of X-linked genes.[4]

To correct this imbalance, mammalian females have evolved a unique mechanism of dosage compensation. In particular, by way of the process called X-chromosome inactivation (XCI), female mammals transcriptionally silence one of their two Xs in a complex and highly coordinated manner.[4]

Genetic Chromosomal

[35]

Here is the original post:
Human genetics - Wikipedia

Posted in Human Genetics | Comments Off on Human genetics – Wikipedia

Whole genome sequencing – Wikipedia

Posted: at 5:20 pm

"Genome sequencing" redirects here. For the sequencing only of DNA, see DNA sequencing.

Whole genome sequencing (also known as WGS, full genome sequencing, complete genome sequencing, or entire genome sequencing) is a laboratory process that determines the complete DNA sequence of an organism's genome at a single time. This entails sequencing all of an organism's chromosomal DNA as well as DNA contained in the mitochondria and, for plants, in the chloroplast.

Whole genome sequencing should not be confused with DNA profiling, which only determines the likelihood that genetic material came from a particular individual or group, and does not contain additional information on genetic relationships, origin or susceptibility to specific diseases.[2] Also unlike full genome sequencing, SNP genotyping covers less than 0.1% of the genome. Almost all truly complete genomes are of microbes; the term "full genome" is thus sometimes used loosely to mean "greater than 95%". The remainder of this article focuses on nearly complete human genomes.

High-throughput genome sequencing technologies have largely been used as a research tool and are currently being introduced in the clinics.[3][4][5] In the future of personalized medicine, whole genome sequence data will be an important tool to guide therapeutic intervention.[6] The tool of gene sequencing at SNP level is also used to pinpoint functional variants from association studies and improve the knowledge available to researchers interested in evolutionary biology, and hence may lay the foundation for predicting disease susceptibility and drug response.

The shift from manual DNA sequencing methods such as Maxam-Gilbert sequencing and Sanger sequencing in the 1970s and 1980s to more rapid, automated sequencing methods in the 1990s played a crucial role in giving scientists the ability to sequence whole genomes.[8]Haemophilus influenzae, a commensal bacterium which resides in the human respiratory tract was the first organism to have its entire genome sequenced (Figure 2.1). The entire genome of this bacterium was published in 1995.[9] The genomes of H. influenzae, other Bacteria, and some Archaea were the first to be sequenced - largely due to their small genome size. H. influenzae has a genome of 1,830,140 base pairs of DNA.[9] In contrast, eukaryotes, both unicellular and multicellular such as Amoeba dubia and humans (Homo sapiens) respectively, have much larger genomes (see C-value paradox).[10]Amoeba dubia has a genome of 700 billion nucleotide pairs spread across thousands of chromosomes.[11] Humans contain fewer nucleotide pairs (about 3.2 billion in each germ cell - note the exact size of the human genome is still being revised) than A. dubia however their genome size far outweighs the genome size of individual bacteria.[12]

The first bacterial and archaeal genomes, including that of H. influenzae, were sequenced by Shotgun sequencing.[9] In 1996, the first eukaryotic genome ( the yeast Saccharomyces cerevisiae) was sequenced. S. cerevisiae, a model organism in biology has a genome of only around 12 million nucleotide pairs,[13] and was the first unicellular eukaryote to have its whole genome sequenced. The first multicellular eukaryote, and animal, to have its whole genome sequenced was the nematode worm: Caenorhabditis elegans in 1998.[14] Eukaryotic genomes are sequenced by several methods including Shotgun sequencing of short DNA fragments and sequencing of larger DNA clones from DNA libraries (see library (biology)) such as Bacterial artificial chromosomes (BACs) and Yeast artificial chromosomes (YACs).[15]

In 1999, the entire DNA sequence of human chromosome 22, the shortest human autosome, was published.[16] By the year 2000, the second animal and second invertebrate (yet first insect) genome was sequenced - that of the fruit fly Drosophila melanogaster - a popular choice of model organism in experimental research.[17] The first plant genome - that of the model organism Arabidopsis thaliana - was also fully sequenced by 2000.[18] By 2001, a draft of the entire human genome sequence was published.[19] The genome of the laboratory mouse Mus musculus was completed in 2002.[20]

In 2004, the Human Genome Project published the human genome.[21]

Currently, thousands of genomes have been sequenced.

Almost any biological sample containing a full copy of the DNAeven a very small amount of DNA or ancient DNAcan provide the genetic material necessary for full genome sequencing. Such samples may include saliva, epithelial cells, bone marrow, hair (as long as the hair contains a hair follicle), seeds, plant leaves, or anything else that has DNA-containing cells.

The genome sequence of a single cell selected from a mixed population of cells can be determined using techniques of single cell genome sequencing. This has important advantages in environmental microbiology in cases where a single cell of a particular microorganism species can be isolated from a mixed population by microscopy on the basis of its morphological or other distinguishing characteristics. In such cases the normally necessary steps of isolation and growth of the organism in culture may be omitted, thus allowing the sequencing of a much greater spectrum of organism genomes.[22]

Single cell genome sequencing is being tested as a method of preimplantation genetic diagnosis, wherein a cell from the embryo created by in vitro fertilization is taken and analyzed before embryo transfer into the uterus.[23] After implantation, cell-free fetal DNA can be taken by simple venipuncture from the mother and used for whole genome sequencing of the fetus.[24]

Sequencing of nearly an entire human genome was first accomplished in 2000 partly through the use of shotgun sequencing technology. While full genome shotgun sequencing for small (40007000 base pair) genomes was already in use in 1979,[25] broader application benefited from pairwise end sequencing, known colloquially as double-barrel shotgun sequencing. As sequencing projects began to take on longer and more complicated genomes, multiple groups began to realize that useful information could be obtained by sequencing both ends of a fragment of DNA. Although sequencing both ends of the same fragment and keeping track of the paired data was more cumbersome than sequencing a single end of two distinct fragments, the knowledge that the two sequences were oriented in opposite directions and were about the length of a fragment apart from each other was valuable in reconstructing the sequence of the original target fragment.

The first published description of the use of paired ends was in 1990 as part of the sequencing of the human HPRT locus,[26] although the use of paired ends was limited to closing gaps after the application of a traditional shotgun sequencing approach. The first theoretical description of a pure pairwise end sequencing strategy, assuming fragments of constant length, was in 1991.[27] In 1995 the innovation of using fragments of varying sizes was introduced,[28] and demonstrated that a pure pairwise end-sequencing strategy would be possible on large targets. The strategy was subsequently adopted by The Institute for Genomic Research (TIGR) to sequence the entire genome of the bacterium Haemophilus influenzae in 1995,[29] and then by Celera Genomics to sequence the entire fruit fly genome in 2000,[30] and subsequently the entire human genome. Applied Biosystems, now called Life Technologies, manufactured the automated capillary sequencers utilized by both Celera Genomics and The Human Genome Project.

While capillary sequencing was the first approach to successfully sequence a nearly full human genome, it is still too expensive and takes too long for commercial purposes. Since 2005 capillary sequencing has been progressively displaced by next-generation sequencing technologies such as Illumina dye sequencing, pyrosequencing, and SMRT sequencing.[31] All of these technologies continue to employ the basic shotgun strategy, namely, parallelization and template generation via genome fragmentation.

Other technologies are emerging, including nanopore technology. Though nanopore sequencing technology is still being refined, its portability and potential capability of generating long reads are of relevance to whole-genome sequencing applications.[32]

In principle, full genome sequencing can provide raw data on all six billion nucleotides in an individual's DNA. However, it does not provide an analysis of what that information means or how it might be utilized in various clinical applications, such as in medicine to help prevent disease. Work toward that goal is continuously moving forward.

Because sequencing generates a lot of data (for example, there are approximately six billion base pairs in each human diploid genome), its output is stored electronically and requires a large amount of computing power and storage capacity. Full genome sequencing would have been nearly impossible before the advent of the microprocessor, computers, and the Information Age.

A 2015 study[33] done at Children's Mercy Hospital in Kansas City detailed the use of full genome sequencing including full analysis. The process took a record breaking 26 hours[34] and was done using Illumina HiSeq machines, the Edico Genome Dragen Processor, and several custom designed software packages. Most of this acceleration was achieved using the newly developed Dragen Processor which brought the analysis time down from 15 hours to 40 minutes.

A number of public and private companies are competing to develop a full genome sequencing platform that is commercially robust for both research and clinical use,[35] including Illumina,[36]Knome,[37]Sequenom,[38]454 Life Sciences,[39] Pacific Biosciences,[40]Complete Genomics,[41]Helicos Biosciences,[42]GE Global Research (General Electric), Affymetrix, IBM, Intelligent Bio-Systems,[43] Life Technologies and Oxford Nanopore Technologies.[44] These companies are heavily financed and backed by venture capitalists, hedge funds, and investment banks.[45][46]

In October 2006, the X Prize Foundation, working in collaboration with the J. Craig Venter Science Foundation, established the Archon X Prize for Genomics,[47] intending to award US$10million to "the first Team that can build a device and use it to sequence 100 human genomes within 10 days or less, with an accuracy of no more than one error in every 1,000,000 bases sequenced, with sequences accurately covering at least 98% of the genome, and at a recurring cost of no more than $1,000per genome".[48] An error rate of 1in 1,000,000bases, out of a total of approximately six billion bases in the human diploid genome, would mean about 6,000errors per genome. The error rates required for widespread clinical use, such as predictive medicine[49] is currently set by over 1,400 clinical single gene sequencing tests[50] (for example, errors in BRCA1 gene for breast cancer risk analysis).

The Archon X Prize for Genomics was cancelled in 2013, before its official start date.[51][52]

In 2007, Applied Biosystems started selling a new type of sequencer called SOLiD System.[53] The technology allowed users to sequence 60 gigabases per run.[54]

In June 2009, Illumina announced that they were launching their own Personal Full Genome Sequencing Service at a depth of 30 for $48,000 per genome.[55][56]

In August 2009, the founder of Helicos Biosciences, Stephen Quake, stated that using the company's Single Molecule Sequencer he sequenced his own full genome for less than $50,000.[57]

In November 2009, Complete Genomics published a peer-reviewed paper in Science demonstrating its ability to sequence a complete human genome for $1,700.[58][59]

In May 2011, Illumina lowered its Full Genome Sequencing service to $5,000 per human genome, or $4,000 if ordering 50 or more.[60] Helicos Biosciences, Pacific Biosciences, Complete Genomics, Illumina, Sequenom, ION Torrent Systems, Halcyon Molecular, NABsys, IBM, and GE Global appear to all be going head to head in the race to commercialize full genome sequencing.[31][61]

A series of publications in 2012 showed the utility of SMRT sequencing from Pacific Biosciences in generating full genome sequences with de novo assembly.[62]

With sequencing costs declining, a number of companies began claiming that their equipment would soon achieve the $1,000 genome: these companies included Life Technologies in January 2012,[63]Oxford Nanopore Technologies in February 2012[64] and Illumina in February 2014.[65][66]

However, as of 2015, the NHGRI estimates the cost of obtaining a whole-genome sequence at around $1,500.[67]

Full genome sequencing provides information on a genome that is orders of magnitude larger than that provided by the previous leader in genotyping technology, DNA arrays. For humans, DNA arrays currently provide genotypic information on up to one million genetic variants,[68][69][70] while full genome sequencing will provide information on all six billion bases in the human genome, or 3,000times more data. Because of this, full genome sequencing is considered a disruptive innovation to the DNA array markets as the accuracy of both range from 99.98% to 99.999% (in non-repetitive DNA regions) and their consumables cost of $5000 per 6 billion base pairs is competitive (for some applications) with DNA arrays ($500per 1 million basepairs).[39]Agilent, another established DNA array manufacturer, is working on targeted (selective region) genome sequencing technologies.[71] It is thought that Affymetrix, the pioneer of array technology in the 1990s, has fallen behind due to significant corporate and stock turbulence and is currently not working on any known full genome sequencing approach.[72][73][74] It is unknown what will happen to the DNA array market once full genome sequencing becomes commercially widespread, especially as companies and laboratories providing this disruptive technology start to realize economies of scale. It is postulated, however, that this new technology may significantly diminish the total market size for arrays and any other sequencing technology once it becomes commonplace for individuals and newborns to have their full genomes sequenced.[75]

Whole genome sequencing has established the mutation frequency for whole human genomes. The mutation frequency in the whole genome between generations for humans (parent to child) is about 70 new mutations per generation.[76][77] An even lower level of variation was found comparing whole genome sequencing in blood cells for a pair of monozygotic (identical twins) 100-year-old centenarians.[78] Only 8 somatic differences were found, though somatic variation occurring in less than 20% of blood cells would be undetected.

In the specifically protein coding regions of the human genome, it is estimated that there are about 0.35 mutations that would change the protein sequence between parent/child generations (less than one mutated protein per generation).[79]

In cancer, mutation frequencies are much higher, due to genome instability. This frequency can further depend on patient age, exposure to DNA damaging agents (such as UV-irradiation or components of tobacco smoke) and the activity/inactivity of DNA repair mechanisms.[80] Furthermore, mutation frequency can vary between cancer types: in germline cells, mutation rates occur at approximately 0.023 mutations per megabase, but this number is much higher in breast cancer (1.18-1.66 mutations per Mb), in lung cancer (17.7) or in melanomas (~33).[81]

Inexpensive, time-efficient full genome sequencing will be a major accomplishment not only for the field of genomics, but for the entire human civilization because, for the first time, individuals will be able to have their entire genome sequenced. Utilizing this information, it is speculated that health care professionals, such as physicians and genetic counselors, will eventually be able to use genomic information to predict what diseases a person may get in the future and attempt to either minimize the impact of that disease or avoid it altogether through the implementation of personalized, preventive medicine. Full genome sequencing will allow health care professionals to analyze the entire human genome of an individual and therefore detect all disease-related genetic variants, regardless of the genetic variant's prevalence or frequency. This will enable the rapidly emerging medical fields of predictive medicine and personalized medicine and will mark a significant leap forward for the clinical genetic revolution. Full genome sequencing is clearly of great importance for research into the basis of genetic disease and has shown significant benefit to a subset of individuals with rare disease in the clinical setting.[82][83][84][85] Illumina's CEO, Jay Flatley, stated in February 2009 that "A complete DNA read-out for every newborn will be technically feasible and affordable in less than five years, promising a revolution in healthcare" and that "by 2019 it will have become routine to map infants' genes when they are born".[86] This potential use of genome sequencing is highly controversial, as it runs counter to established ethical norms for predictive genetic testing of asymptomatic minors that have been well established in the fields of medical genetics and genetic counseling.[87][88][89][90] The traditional guidelines for genetic testing have been developed over the course of several decades since it first became possible to test for genetic markers associated with disease, prior to the advent of cost-effective, comprehensive genetic screening. It is established that norms, such as in the sciences and the field of genetics, are subject to change and evolve over time.[91][92] It is unknown whether traditional norms practiced in medical genetics today will be altered by new technological advancements such as full genome sequencing.

In March 2010, researchers from the Medical College of Wisconsin announced the first successful use of whole-genome sequencing to inform the treatment of a patient.[93][94]

Currently available newborn screening for childhood diseases allows detection of rare disorders that can be prevented or better treated by early detection and intervention. Specific genetic tests are also available to determine an etiology when a child's symptoms appear to have a genetic basis. Full genome sequencing, in addition has the potential to reveal a large amount of information (such as carrier status for autosomal recessive disorders, genetic risk factors for complex adult-onset diseases, and other predictive medical and non-medical information) that is currently not completely understood, may not be clinically useful to the child during childhood, and may not necessarily be wanted by the individual upon reaching adulthood.[95] In addition to predicting disease risk in childhood, genetic testing may have other benefits (such as discovery of non-paternity) but may also have potential downsides (genetic discrimination, loss of anonymity, and psychological impacts).[96] Many publications regarding ethical guidelines for predictive genetic testing of asymptomatic minors may therefore have more to do with protecting minors and preserving the individual's privacy and autonomy to know or not to know their genetic information, than with the technology that makes the tests themselves possible.[97]

Due to recent cost reductions (see above) whole genome sequencing has become a realistic application in DNA diagnostics. In 2013, the 3Gb-TEST consortium obtained funding from the European Union to prepare the health care system for these innovations in DNA diagnostics.[98][99]Quality assessment schemes, Health technology assessment and guidelines have to be in place. The 3Gb-TEST consortium has identified the analysis and interpretation of sequence data as the most complicated step in the diagnostic process.[100] At the Consortium meeting in Athens in September 2014, the Consortium coined the word genotranslation for this crucial step. This step leads to a so-called genoreport. Guidelines are needed to determine the required content of these reports.

The majority of ethicists insist that the privacy of individuals undergoing genetic testing must be protected under all circumstances.[101] Data obtained from whole genome sequencing can not only reveal much information about the individual who is the source of DNA, but it can also reveal much probabilistic information about the DNA sequence of close genetic relatives.[102] Furthermore, the data obtained from whole genome sequencing can also reveal much useful predictive information about the relatives present and future health risks.[103] This raises important questions about what obligations, if any, are owed to the family members of the individuals who are undergoing genetic testing. In the Western/European society, tested individuals are usually encouraged to share important information on the genetic diagnosis with their close relatives since the importance of the genetic diagnosis for offspring and other close relatives is usually one of the reasons for seeking a genetic testing in the first place.[101] Nevertheless, a major ethical dilemma can develop when the patients refuse to share information on a diagnosis that is made for serious genetic disorder that is highly preventable and where there is a high risk to relatives carrying the same disease mutation.[102] Under such circumstances, the clinician may suspect that the relatives would rather know of the diagnosis and hence the clinician can face a conflict of interest with respect to patient-doctor confidentiality.[102]

Another major privacy concern is the scientific need to put information on patient's genotypes and phenotypes into the public scientific databases such as the locus specific databases.[102] Although only anonymous patient data are submitted to the locus specific databases, patients might still be identifiable by their relatives in the case of finding a rare disease or a rare missense mutation.[102]

The first nearly complete human genomes sequenced were two caucasians in 2007 (J. Craig Venter at 7.5-fold coverage,[104][105][106] and James Watson at 7.4-fold).[107][108][109] This was followed in 2008 by sequencing of an anonymous Han Chinese man (at 36-fold),[110] a Yoruban man from Nigeria (at 30-fold),[111] and a female caucasian Leukemia patient (at 33 and 14-fold coverage for tumor and normal tissues).[112]Steve Jobs was among the first 20 people to have their whole genome sequenced, reportedly for the cost of $100,000.[113] As of June 2012[update], there are 69 nearly complete human genomes publicly available.[114]Commercialization of full genome sequencing is in an early stage and growing rapidly.

Continue reading here:
Whole genome sequencing - Wikipedia

Posted in Genome | Comments Off on Whole genome sequencing – Wikipedia

List of countries by life expectancy – Wikipedia

Posted: at 5:20 pm

This is a collection of lists of countries by average life expectancy at birth.

Life expectancy equals the average number of years a person born in a given country is expected to live if mortality rates at each age were to remain steady in the future. The life expectancy is shown separately for males and females, as well as a combined figure. Several non-sovereign entities are also included in this list too.

The figures reflect the quality of healthcare in the countries listed as well as other factors including ongoing wars, obesity, and HIV infections.[citation needed]

Worldwide, the average life expectancy at birth was 71.0 years (68 years and 6 months for males and 73 years and 6 months for females) over the period 20102013 according to United Nations World Population Prospects 2012 Revision,[3] or 70.7 years (68.2 years for males and 73.2 years for females) for 2009 according to The World Factbook.[4] According to the World Health Organization (WHO), women on average live longer than men in all countries, with the exception of Tonga.

The countries with the lowest overall life expectancies per the WHO are Sierra Leone, the Central African Republic, the Democratic Republic of the Congo, Guinea-Bissau, Lesotho, Somalia, Swaziland, Angola, Chad, Mali, Burundi, Cameroon, and Mozambique. Of those countries, only Lesotho, Swaziland, and Mozambique in 2011 were suffering from an HIV prevalence rate of greater than 10 percent in the 1549 age group.[5]

Comparing life expectancies from birth across countries can be problematic. There are differing definitions of live birth vs stillbirth even among more developed countries and less developed countries often have poor reporting.[6]

2015 data[7] published in May 2016.[8]

HALE: Health-adjusted life expectancy[9]

On July 2015, the Population Division of the United Nations Department of Economic and Social Affairs (UN DESA), released World Population Prospects, The 2015 Revision.[3] The following table shows the life expectancy at birth for the period 2010 to 2015.

over 80

77.5-80.0

75.0-77.5

72.5-75.0

70.0-72.5

67.5-70.0

65.0-67.5

60-65

55-60

50-55

45-50

under 45

not available

The Global Burden of Disease 2010 study published updated figures in 2012,[10] including recalculations of life expectancies[11] which differ substantially in places from the UN estimates for 2010 (reasons for this are discussed in the freely available appendix to the paper, pages 2527, currently not available). Although no estimate is given for the sexes combined, for the first time life expectancy estimates have included uncertainty intervals.

>80

>77.5

>75

>72.5

>70

>67.5

>65

>60

>55

>50

>45

>40

<40

The US CIA published the following life expectancy data in its annual world factbook 2012.[1]

Figures are from the CIA World Factbook 2009[1] and from the 2010 revision of the United Nations World Population Prospects report, for 20052010,[3] (data viewable at http://esa.un.org/wpp/Sorting-Tables/tab-sorting_mortality.htm, with equivalent spreadsheets here, here, and here).

Only countries/territories with a population of 100,000 or more in 2010 are included in the United Nations list. WHO database 2013 http://www.who.int/gho/publications/world_health_statistics/EN_WHS2013_Full.pdf

Continue reading here:
List of countries by life expectancy - Wikipedia

Posted in Human Longevity | Comments Off on List of countries by life expectancy – Wikipedia

Ron Paul: The real meaning of populism – CNN.com

Posted: at 5:20 pm

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

Louisa Hill, 3, walks onto a stage in Hanover, New Hampshire, as Clinton speaks on July 3, 2015.

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

Bush is seen on a camera at the Iowa State Fair on August 14, 2015.

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

Cruz speaks during the annual banquet of the Iowa Faith & Freedom Coalition on September 19, 2015.

The 2016 presidential race, in photos

The 2016 presidential race, in photos

Clinton, right, appears on an episode of "Saturday Night Live" opposite Kate McKinnon, who has been playing Clinton during the campaign, on October 3, 2015.

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

Trump is flanked by impersonators Taran Killam, left, and Darrell Hammond during his "Saturday Night Live" monologue on November 7, 2015.

The 2016 presidential race, in photos

The 2016 presidential race, in photos

Sanders sits in an Atlanta cafe with rapper Killer Mike on November 23, 2015. The rapper introduced Sanders at a campaign event later that day.

The 2016 presidential race, in photos

Hidayah Martinez Jaka wears an American flag hijab as Democratic presidential candidate Martin O'Malley speaks at a mosque in Sterling, Virginia, on December 11, 2015.

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

A supporter reacts as Trump signs her poster during a campaign rally in Lowell, Massachusetts, on January 4, 2016.

The 2016 presidential race, in photos

A protester is removed by security personnel during a Trump campaign event in Rock Hill, South Carolina, on January 8, 2016.

The 2016 presidential race, in photos

While visiting the Civil Rights Institute in Birmingham, Alabama, on January 18, 2016, Sanders touches the actual jail bars that the Rev. Martin Luther King Jr. was behind when he wrote his "Letter from Birmingham Jail" in 1963.

The 2016 presidential race, in photos

The 2016 presidential race, in photos

A giant Trump poster is illuminated outside a home in Des Moines, Iowa, on January 28, 2016.

The 2016 presidential race, in photos

Republican presidential candidate Rick Santorum, second from right, drinks a beer at a pub in Waukee, Iowa, on January 28, 2016. The former U.S. senator from Pennsylvania also ran in 2012.

The 2016 presidential race, in photos

A woman in a Princess Leia costume makes a "Star Wars"-themed plea for Sanders during a campaign rally in Cedar Rapids, Iowa, on January 30, 2016.

The 2016 presidential race, in photos

The 2016 presidential race, in photos

Sanders speaks during a campaign event in Des Moines, Iowa, on January 31, 2016.

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

Clinton plays goalie during a campaign stop at an indoor-soccer center in Las Vegas on February 13, 2016. After her loss in New Hampshire, Clinton rebounded to win the Nevada primary on February 20.

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

Cruz speaks from a truck bed at a rally in Pahrump, Nevada, on February 21, 2016.

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

Bernie Sanders is joined by his wife, Jane, at a rally in Burlington, Vermont, on March 1, 2016. Sanders won his state's primary on Super Tuesday, but he lost to Clinton in seven of the other 10 states.

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

Ohio Gov. John Kasich, one of the Republican presidential candidates, poses with a Sanders impersonator at the end of a town-hall meeting in Palatine, Illinois, on March 9, 2016.

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

Kasich celebrates his Ohio primary victory on March 15, 2016. It was the only win of his campaign.

The 2016 presidential race, in photos

The 2016 presidential race, in photos

Cruz laughs at a poster while speaking a town-hall event in Madison, Wisconsin, on March 30, 2016.

The 2016 presidential race, in photos

The 2016 presidential race, in photos

Kasich has lunch at a deli during a campaign stop in New York on April 7, 2016.

The 2016 presidential race, in photos

Clinton shakes hands during a campaign event in Wilmington, Delaware, on April 25, 2016.

The 2016 presidential race, in photos

The 2016 presidential race, in photos

The 2016 presidential race, in photos

Continue reading here:
Ron Paul: The real meaning of populism - CNN.com

Posted in Ron Paul | Comments Off on Ron Paul: The real meaning of populism – CNN.com

Genetic Engineering | MSPCA-Angell

Posted: November 10, 2016 at 5:32 pm

The MSPCAbelieves scientists ability to clone animals, to alter the genetic makeup of an animal, and to transfer pieces of genetic material from one species to another raises serious concerns for animals and humans alike.

This pagewill explore issues related to genetic engineering, transgenic animals, and cloned animals. It will examine the implications of genetic engineering on human and animal welfare and will touch on some related moral and ethical concerns that our society has so far failed to completely address.

Definitions

Problems related to the physical and psychological well-being of cloned and transgenic animals, significant ethical concerns about the direct manipulation of genetic material, and questions about the value of life itself must all be carefully weighed against the potential benefits of genetic engineering for disease research, agricultural purposes, vaccine development, pharmaceutical products, and organ transplants.

Genetic engineering is, as yet, an imperfect science that yields imperfect results.

Changes in animal growth and development brought about by genetic engineering and cloning are less predictable, more rapid, and often more debilitating than changes brought about through the traditional process of selective breeding.

This is especially apparent with cloning. Success rates are incredibly low; on average, less than 5% of cloned embryos are born and survive.

Clones are created at a great cost to animals. The clones that are successful, as well as those that do not survive and the surrogates who carry them, suffer greatly.Many of the cloned animals that do survive are plagued by severe health problems.

Offspring suffer from severe birth defects such as Large Offspring Syndrome (LOS), in which the cloned offspring are significantly larger than normal fetuses; hydrops, a typically fatal condition in which the mother or the fetus swells with fluid; respiratory distress; developmental problems; malformed organs; musculoskeletal deformities; or weakened immune systems, to name only a few.

Additionally, surrogates are subjected to repeated invasive procedures to harvest their eggs, implant embryos, or due to the offsprings birth defects surgical intervention to deliver their offspring. All of these problems occur at much higher rates than for offspring produced via traditional breeding methods.

Cloning increases existing animal welfare and environmental concerns related to animal agriculture.

In 1996, the birth of the ewe, Dolly, marked the first successful cloning of a mammal from adult cells. At the time of her birth, the researchers who created Dolly acknowledged the inefficiency of the new technology: it took 277 attempts to create this one sheep, and of these, only 29 early embryos developed, and an even smaller number of these developed into live fetuses. In the end, Dolly was the sole surviving clone. She was euthanized in 2003 at just 6 years of age, about half as old as sheep are expected to live, and with health problems more common in older sheep.

Since Dollys creation, the process of cloning has not demonstrated great improvement in efficiency or rates of success. A 2003 review of cloning in cattle found that less than 5% of cloned embryos transferred into surrogate cows survived; a 2016 study showedno noticeable increase in efficiency, with the success rate being about 1%.

Currently, research is focused on cloning for agricultural purposes. Used alone, or in concert with genetic engineering, the objective is to clone the best stock to reproduce whole herds or flocks with desired uniform characteristics of a specific trait, such as fast growth, leaner meat, or higher milk production. Cloning is often pursued to produce animals that grow faster so they can be slaughtered sooner and to raise more animals in a smaller space.

For example, transgenic fish are engineered to grow larger at a faster rate and cows injected with genetically engineered products to increase their productivity. Another example of this is the use of the genetically engineered drug, bovine growth hormone (BGH or BST) to increase milk production in dairy cows. This has also been associated with increased cases of udder disease, spontaneous abortion, lameness, and shortened lifespan. The use of BGH is controversial; many countries (such as Canada, Japan, Australia, and countries in the EU) do not allow it, and many consumers try to avoid it.A rise in transgenic animals used for agriculture will only exacerbate current animal welfare and environmental concerns with existing intensive farming operations.(For more information on farming and animal welfare, visit the MSPCAs Farm Animal Welfare page.)

Much remains unknown about thepotential environmental impacts of widespread cloning of animals. The creation of genetically identical animals leads to concerns about limited agricultural animal gene pools. The effects of creating uniform herds of animals and the resulting loss of biodiversity, have significant implications for the environment and for the ability of cloned herds to withstand diseases. This could make an impact on the entireagriculture industry and human food chain.

These issues became especiallyconcerning when, in 2008, the Federal Drug Administration not only approved the sale of meat from the offspring of cloned animals, but also did not require that it be labeled as such. There have been few published studies that examine the composition of milk, meat, or eggs from cloned animals or their progeny, including the safety of eating those products. The health problems associated with cloned animals, particularly those that appear healthy but have concealed illnesses or problems that appear unexpectedly later in life, could potentially pose risks to the safety of the food products derived from those animals.

Genetically Engineered Pets

Companion animals have also been cloned. The first cloned cat, CC, was created in 2001. CCs creation marked the beginning of the pet cloning industry, in which pet owners could pay to bank DNA from their companion dogs and cats to be cloned in the future. In 2005, the first cloned dog was created; later, the first commercially cloned dog followed at a cost of $50,000. Many consumers assume that cloning will produce a carbon copy of their beloved pet, but this is not the case. Even though the animals are genetically identical, they often do not resemble each other physically or behaviorally.

To date, the pet cloning industry has not been largely successful. However, efforts to make cloning a successful commercial venture are still being put forth.RBio (formerly RNL Bio), a Korean biotechnology company, planned to create a research center that would produce 1,000 cloned dogs annually by 2013. However, RBio, considered a black market cloner, failed to make any significant strides in itscloning endeavors and seems to have been replaced by other companies, such as South Korean-based Sooam Biotech, now the worlds leader in commercial pet cloning. Since 2006, Sooam has cloned over 800 dogs, in addition to other animals, such as cattle and pigs, for breed preservation and medical research.

While South Korean animal cloning expands, the interest in companion animal cloning in the United States continues to remain low. In 2009, the American company BioArts ceased its dog cloning services and ended its partnership with Sooam, stating in a press release that cloning procedures were still underdeveloped and that the cloning market itself was weak and unethical. Companion animal cloning causes concern not only because of the welfare issues inherent in the cloning process, but also because of its potential to contribute to pet overpopulation problem in the US, as millions of animals in shelters wait for homes.

Cloning and Medical Research

Cloning is also used to produce copies of transgenic animals that have been created to mimic certain human diseases. The transgenic animals are created, then cloned, producing a supply of animals for biomedical testing.

A 1980 U.S. Supreme Court decision to permit the patenting of a microorganism that could digest crude oil had a great impact on animal welfare and genetic engineering. Until that time, the U.S. Patent Office had prohibited the patenting of living organisms. However, following the Supreme Court decision, the Patent Office interpreted this ruling to extend to the patenting of all higher life forms, paving the way for a tremendous explosion of corporate investment in genetic engineering research.

In 1988, the first animal patent was issued to Harvard University for the Oncomouse, a transgenic mouse genetically modified to be more prone to develop cancers mimicking human disease. Since then, millions of transgenic mice have been produced. Transgenic rats, rabbits, monkeys, fish, chickens, pigs, sheep, goats, cows, horses, cats, dogs, and other animals have also been created.

Both expected and unexpected results occur in the process of inserting new genetic material into an egg cell. Defective offspring can suffer from chromosomal abnormalities that can cause cancer, fatal bleeding disorders, inability to reproduce, early uterine death, lack of ability to nurse, and such diseases as arthritis, diabetes, liver disease, and kidney disease.

The production of transgenic animals is of concern because genetic engineering is often used to create animals with diseases that cause intense suffering. Among the diseases that can be produced in genetically engineered research mice are diabetes, cancer, cystic fibrosis, sickle-cell anemia, Huntingtons disease, Alzheimers disease, and a rare but severe neurological condition called Lesch-Nyhansyndromethat causes the sufferer to self-mutilate. Animals carrying the genes for these diseases can suffer for long periods of time, both in the laboratory and while they are kept on the shelf by laboratory animal suppliers.

Another reason for the production of transgenic animals is pharming, in which sheep and goats are modified to produce pharmaceuticals in their milk. In 2009, the first drug produced by genetically engineered animals was approved by the FDA. The drug ATryn, used to prevent fatal blood clots in humans, is derived from goats into which a segment of human DNA has been inserted, causing them to produce an anticoagulant protein in their milk. This marks the first time a drug has been manufactured from a herd of animals created specifically to produce a pharmaceutical.

A company has also manufactured a drug produced in the milk of transgenic rabbits to treat a dangerous tissue swelling caused by a human protein deficiency. Yet another pharmaceutical manufacturer, PharmAnthene, was funded by the US Department of Defense to develop genetically engineered goats whose milk produces proteins used in a drug to treat nerve gas poisoning. The FDA also approved a drug whose primary proteins are also found in the milk of genetically engineered goats, who are kept at a farm in Framingham, Massachusetts. Additionally, a herd of cattle was recently developed that produces milk containing proteins that help to treat human emphysema. These animals are essentially used as pharmaceutical-production machines to manufacture only those substances they were genetically modified to produce; they are not used as part of the normal food supply chain for items such as meat or milk.

The transfer of animal tissues from one species to another raises potentially serious health issues for animals and humans alike.

Some animals are also genetically modified to produce tissues and organs to be used for human transplant purposes (xenotransplantation). Much effort is being focused in this area as the demand for human organs for transplantation far exceeds the supply, with pigs the current focus of this research. While efforts to date have been hampered by a pig protein that can cause organ rejection by the recipients immune system, efforts are underway to develop genetically modified swine with a human protein that would mitigate the chance of organ rejection.

Little is known about the ways in which diseases can be spread from one species to another, raising concerns for both animals and people, and calling into question the safety of using transgenic pigs to supply organs for human transplant purposes. Scientists have identified various viruses common in the heart, spleen, and kidneys of pigs that could infect human cells. In addition, new research is shedding light on particles called prions that, along with viruses and bacteria, may transmit fatal diseases between animals and from animals to humans.

Acknowledging the potential for transmission of viruses from animals to humans, the National Institutes of Health, a part of the U.S. Department of Health and Human Services,issued a moratorium in 2015 onxenotransplantation until the risks are better understood, ceasing funding until more research has been carried out. With the science of genetic engineering, the possibilities are endless, but so too are the risks and concerns.

Genetic engineering research has broad ethical and moral ramifications with few established societal guidelines.

While biotechnology has been quietly revolutionizing the science for decades, public debate in the United Statesover the moral, ethical, and physical effects of this research has been insufficient. To quote Colorado State University Philosopher Bernard Rollin, We cannot control technology if we do not understand it, and we cannot understand it without a careful discussion of the moral questions to which it gives rise.

Research into non-animal methods of achieving some of the same goals looks promising.

Researchers in the U.S. and elsewhere have found ways togenetically engineer cereal grains to produce human proteins. One example of this, developed in the early 2000s, is a strain of rice that can produce a human protein used to treat cystic fibrosis. Wheat, corn, and barley may also be able to be used in similar ways at dramatically lower financial and ethical costs than genetically engineering animals for this purpose.

Originally posted here:
Genetic Engineering | MSPCA-Angell

Posted in Genetic Engineering | Comments Off on Genetic Engineering | MSPCA-Angell

Genetic Engineering and GM Crops – Pocket K | ISAAA.org

Posted: at 5:32 pm

Over the last 50 years, the field of genetic engineering has developed rapidly due to the greater understanding of deoxyribonucleic acid (DNA) as the chemical double helix code from which genes are made. The term genetic engineering is used to describe the process by which the genetic makeup of an organism can be altered using recombinant DNA technology. This involves the use of laboratory tools to insert, alter, or cut out pieces of DNA that contain one or more genes of interest.

Developing plant varieties expressing good agronomic characteristics is the ultimate goal of plant breeders. With conventional plant breeding, however, there is little or no guarantee of obtaining any particular gene combination from the millions of crosses generated. Undesirable genes can be transferred along with desirable genes; or, while one desirable gene is gained, another is lost because the genes of both parents are mixed together and re-assorted more or less randomly in the offspring. These problems limit the improvements that plant breeders can achieve.

In contrast, genetic engineering allows the direct transfer of one or just a few genes of interest, between either closely or distantly related organisms to obtain the desired agronomic trait (Figure 1). Not all genetic engineering techniques involve inserting DNA from other organisms. Plants may also be modified by removing or switching off their own particular genes.

Source: Agricultural Biotechnology (A Lot More than Just GM Crops). http://www.isaaa.org/resources/publications/agricultural_biotechnology/download/.

Genes are molecules of DNA that code for distinct traits or characteristics. For instance, a particular gene sequence is responsible for the color of a flower or a plants ability to fight a disease or thrive in extreme environment.

The sharing of DNA among living forms is well documented as a natural phenomenon. For thousands of years, genes have moved from one organism to another. For example, Agrobacterium tumefaciens, a soil bacterium known as natures own genetic engineer, has the natural ability to genetically engineer plants. It causes crown gall disease in a wide range of broad-leaved plants, such as apple, pear, peach, cherry, almond, raspberry, and roses. The disease gains its name from the large tumor-like swellings (galls) that typically occur at the crown of the plant, just above soil level. Basically, the bacterium transfers part of its DNA to the plant, and this DNA integrates into the plants genome, causing the production of tumors and associated changes in plant metabolism.

Genetic engineering techniques are used only when all other techniques have been exhausted, i.e. when the trait to be introduced is not present in the germplasm of the crop; the trait is very difficult to improve by conventional breeding methods; and when it will take a very long time to introduce and/or improve such trait in the crop by conventional breeding methods (see Figure 2). Crops developed through genetic engineering are commonly known as transgenic crops or genetically modified (GM) crops.

Modern plant breeding is a multi-disciplinary and coordinated process where a large number of tools and elements of conventional breeding techniques, bioinformatics, molecular genetics, molecular biology, and genetic engineering are utilized and integrated.

Figure 2: Modern Plant Breeding

Source: DANIDA, 2002.

Although there are many diverse and complex techniques involved in genetic engineering, its basic principles are reasonably simple. There are five major steps in the development of a genetically engineered crop. But for every step, it is very important to know the biochemical and physiological mechanisms of action, regulation of gene expression, and safety of the gene and the gene product to be utilized. Even before a genetically engineered crop is made available for commercial use, it has to pass through rigorous safety and risk assessment procedures.

The first step is the extraction of DNA from the organism known to have the trait of interest. The second step is gene cloning, which will isolate the gene of interest from the entire extracted DNA, followed by mass-production of the cloned gene in a host cell. Once it is cloned, the gene of interest is designed and packaged so that it can be controlled and properly expressed once inside the host plant. The modified gene will then be mass-produced in a host cell in order to make thousands of copies. When the gene package is ready, it can then be introduced into the cells of the plant being modified through a process called transformation. The most common methods used to introduce the gene package into plant cells include biolistic transformation (using a gene gun) or Agrobacterium-mediated transformation. Once the inserted gene is stable, inherited, and expressed in subsequent generations, then the plant is considered a transgenic. Backcross breeding is the final step in the genetic engineering process, where the transgenic crop is crossed with a variety that possesses important agronomic traits, and selected in order to obtain high quality plants that express the inserted gene in a desired manner.

The length of time in developing transgenic plant depends upon the gene, crop species, available resources, and regulatory approval. It may take 6-15 years before a new transgenic hybrid is ready for commercial release.

Transgenic crops have been planted in different countries for twenty years, starting from 1996 to 2015. About 179.7 million hectares was planted in 2015 to transgenic crops with high market value, such as herbicide tolerant soybean, maize, cotton, and canola; insect resistant maize, cotton, potato, and rice; and virus resistant squash and papaya. With genetic engineering, more than one trait can be incorporated or stacked into a plant. Transgenic crops with combined traits are also available commercially. These include herbicide tolerant and insect resistant maize, soybean and cotton.

To date, commercial GM crops have delivered benefits in crop production, but there are also a number of products in the pipeline which will make more direct contributions to food quality, environmental benefits, pharmaceutical production, and non-food crops. Examples of these products include: rice with higher levels of iron and beta-carotene (an important micronutrient which is converted to vitamin A in the body); long life banana that ripens faster on the tree and can therefore be harvested earlier; tomatoes with high levels of flavonols, which are powerful antioxidants; arsenic-tolerant plants; edible vaccines from fruit and vegetables; and low lignin trees for paper making.

*August 2016

Read the original post:
Genetic Engineering and GM Crops - Pocket K | ISAAA.org

Posted in Genetic Engineering | Comments Off on Genetic Engineering and GM Crops – Pocket K | ISAAA.org

Psoriasis – Causes, Symptoms and Treatment – Health.com …

Posted: November 8, 2016 at 3:32 pm

Psoriasis is a skin condition that is often misunderstood; people who have psoriasis can face prejudice and discrimination. The biggest misconception about psoriasis is that it is contagious or that it's "just a skin disease."

Psoriasis is actually an autoimmune disease, which means that a broken immune system sees your skin as an enemy and attacks it relentlessly. As a result, skin cells that would normally take weeks to grow and reach the outer surface of your skin now only take days. This leaves an excess of skin cells on your body, causing the hallmark raised red, white, or silvery patches on your skin.

No one knows exactly why the immune system goes awry. Some cases may be genetic but many are probably a combination of genetic and environmental causes such as stress, infection, medication side effects or even something as seemingly simple as a bug bite. Having a family history of psoriasis, being obese and being a smoker all increase the risk of developing the disease.

Psoriasis is chronic, meaning it stays with you throughout your life. More than 7 million Americans, both men and women, have psoriasis and most develop it between the ages of 15 and 35.

There are five types of psoriasis, the most common being plaque psoriasis. Other forms are guttate, inverse, pustular and erythrodermic, all of which have slightly different symptoms and may appear on the skin of different parts of the body. You can have more than one type of psoriasis at a time.

Psoriasis can affect much more than the skin. About 40% of psoriasis sufferers go on to develop psoriatic arthritis in their joints. Others may develop type 2 diabetes, heart disease and other autoimmune diseases. And like other chronic diseases, psoriasis can lead to depression and damaged self esteem.

View original post here:
Psoriasis - Causes, Symptoms and Treatment - Health.com ...

Posted in Psoriasis | Comments Off on Psoriasis – Causes, Symptoms and Treatment – Health.com …

Pandora Internet Radio – Listen to Free Music You’ll Love

Posted: November 2, 2016 at 6:56 am

It is taking longer than expected to fetch the next song to play. The music should be playing soon. If you get tired of waiting, you can try reloading your browser.

Please ensure you are using the latest Flash Player.

If you are unable or do not wish to upgrade your Flash Player, please try a different browser.

Your Pandora Plus subscription will expire shortly.

Your Pandora Plus trial will expire shortly.

Your Pandora Plus trial subscription will expire shortly. Upgrade to continue unlimited, ad-free listening.

You've listened to hours of Pandora this month. Consider upgrading to Pandora Plus.

Your music will be right back

Don't have a Pandora account? Sign up

Already have a Pandora account? Log In

We're sorry, but a browser plugin or firewall may be preventing Pandora from loading.

In order to use Pandora internet radio, please upgrade to a more current browser.

Please check our Help page for more information.

It looks like your browser does not support modern SSL/TLS. Please upgrade your browser.

If you need help, please email: pandora-support@pandora.com.

In order to use Pandora internet radio, please upgrade to a more current browser or install a newer version of Flash (v.10 or later).

In order to use Pandora internet radio, please install Adobe Flash (v.10 or later).

[75, 77, 114, 70, 103, 66, 90, 105, 89, 127, 64, 112, 81, 113, 103, 93, 80, 92, 119, 84, 65, 122, 65, 80, 108, 94, 100, 82, 122, 96, 92, 124, 88, 122, 104, 97, 81, 70, 115, 90, 119, 121, 97, 65, 109, 96, 122, 118, 80, 116, 65, 108, 104, 102, 96, 113, 109, 122, 103, 80, 102, 78, 103, 120, 92, 108, 123, 89, 126, 72, 77, 101, 100, 126, 74, 101, 69, 84, 77, 88, 87, 116, 78, 119, 127, 93, 64, 77, 73, 77, 88, 67, 83, 127, 93, 88, 121, 65, 126, 108, 98, 104, 86, 87, 69, 119, 101, 84, 100, 88, 110, 99, 75, 80, 115, 113, 80, 97, 106, 123, 82, 90, 83, 119, 106, 111, 109, 121, 73, 121, 78, 91, 90, 101, 64, 85, 99, 108, 100, 76, 114, 86, 103, 88, 68, 92, 100, 70, 92, 125, 78, 116, 69, 126, 116, 87, 121, 90, 112, 114, 87, 99, 120, 108, 109, 82, 98, 117, 123, 100, 126, 95, 127, 87, 92, 99, 72, 69, 107, 98, 90, 110, 111, 104, 87, 83, 123, 127, 98, 86, 100, 86, 86, 117, 110, 123, 108, 73, 86, 124, 120, 81, 87, 96, 67, 120, 81, 101, 107, 78, 126, 76, 93, 95, 92, 122, 73, 90, 106, 68, 95, 113, 103, 73, 75, 117, 99, 122, 77, 111, 123, 119, 74, 65, 74, 120, 74, 66, 64, 75, 102, 113, 78, 68, 76, 64, 95, 108, 98, 74, 84, 105, 64, 72, 70, 102, 121, 82, 118, 111, 98, 106, 109, 117, 100, 91, 89, 88, 107, 125, 72, 96, 69, 122, 115, 122, 70, 101, 112, 65, 97, 114, 100, 73, 118, 93, 67, 127, 119, 79, 73, 101, 83, 112, 108, 91, 82, 94, 118, 82, 89, 94, 116, 116, 79, 68, 83, 124, 81, 71, 101, 124, 87, 117, 73, 116, 95, 100, 116, 123, 85, 93, 90, 102, 112, 68, 109, 93, 120, 113, 68, 78, 64, 111, 87, 122, 71, 125, 97, 65, 122, 76, 100, 100, 126, 90, 109, 121, 90, 83, 87, 117, 100, 70, 86, 97, 125, 76, 97, 73, 111, 116, 92, 108, 74, 87, 65, 122, 106, 124, 92, 111, 127, 115, 81, 94, 117, 125, 69, 109, 90, 104, 126, 75, 73, 69, 106, 81, 106, 93, 104, 67, 69, 89, 89, 120, 93, 96, 78, 124, 64, 103, 102, 119, 105, 127, 127, 78, 123, 77, 107, 84, 74, 114, 115, 111, 125, 116, 73, 92, 116, 84, 110, 75, 91, 80, 106, 83, 80, 82, 66, 73, 107, 111, 90, 115, 111, 78, 88, 76, 77, 110, 88, 82, 102, 78, 116, 93, 80, 104, 115, 114, 116, 104, 72, 115, 105, 104, 88, 107, 85, 82, 77, 93, 78, 80, 116, 83, 78, 111, 82, 98, 65, 102, 99, 115, 110, 104, 97, 88, 86, 87, 117, 88, 98, 82, 101, 97, 93, 79, 101, 105, 82, 85, 83, 123, 106, 111, 68, 79, 100, 95, 87, 98, 71, 116, 99, 68, 71, 115, 75, 78]

In order to use Pandora internet radio, please enable your browser's JavaScript support.

The rest is here:
Pandora Internet Radio - Listen to Free Music You'll Love

Posted in Genome | Comments Off on Pandora Internet Radio – Listen to Free Music You’ll Love

Genetic Medicine | Department of Pediatrics | University …

Posted: at 6:56 am

Leadership

Michael Bamshad, MD Professor Division Chief

The Division of Genetic Medicine is committed to providing an outstanding level of patient care, education and research. The faculty have diverse interests and are drawn from several disciplines including clinical genetics, molecular genetics, biochemical genetics, human embryology/teratology and neurology.

A large clinical program of medical genetics operates from Seattle Childrens Hospital staffed by faculty from the Division. These clinical activities concentrate on pediatric genetics but also encompass adult and fetal consultations. At Seattle Children's full IP consultations are available and general genetics clinics occur regularly. Consultative services are also provided to the University of Washington Medical Center and Swedish Hospital. In addition, a variety of interdisciplinary clinical services are provided at Childrens including cardiovascular genetics, skeletal dysplasia, neurofibromatosis, craniofacial genetics, gender disorders, neurogenetics and biochemical genetics as well as others. A very large regional genetics service sponsored by state Departments of Health are provided to multiple outreach clinical sites in both Alaska and Washington.

Our research holds the promise for both continued development of improved molecular diagnostic tools and successful treatment of inherited diseases. Research in the Division is highly patient-driven. It often begins with a physician identifying a particular patients problems and subsequently taking that problem into a laboratory setting for further analysis. The Division has a strong research focus with established research programs in medical genetics information systems, neurogenetic disorders, fetal alcohol syndrome, neuromuscular diseases, human teratology, population genetics/evolution and gene therapy.

The Division offers comprehensive training for medical students, residents, and postdoctoral fellows in any of the areas of our clinical and research programs relevant to medical genetics. Medical Genetics Training Website

Margaret L.P. Adam, MD Associate Professor mpa5@u.washington.edu

Read more from the original source:
Genetic Medicine | Department of Pediatrics | University ...

Posted in Gene Medicine | Comments Off on Genetic Medicine | Department of Pediatrics | University …

Medical genetics – Wikipedia

Posted: at 6:56 am

Medical genetics is the branch of medicine that involves the diagnosis and management of hereditary disorders. Medical genetics differs from human genetics in that human genetics is a field of scientific research that may or may not apply to medicine, while medical genetics refers to the application of genetics to medical care. For example, research on the causes and inheritance of genetic disorders would be considered within both human genetics and medical genetics, while the diagnosis, management, and counselling people with genetic disorders would be considered part of medical genetics.

In contrast, the study of typically non-medical phenotypes such as the genetics of eye color would be considered part of human genetics, but not necessarily relevant to medical genetics (except in situations such as albinism). Genetic medicine is a newer term for medical genetics and incorporates areas such as gene therapy, personalized medicine, and the rapidly emerging new medical specialty, predictive medicine.

Medical genetics encompasses many different areas, including clinical practice of physicians, genetic counselors, and nutritionists, clinical diagnostic laboratory activities, and research into the causes and inheritance of genetic disorders. Examples of conditions that fall within the scope of medical genetics include birth defects and dysmorphology, mental retardation, autism, and mitochondrial disorders, skeletal dysplasia, connective tissue disorders, cancer genetics, teratogens, and prenatal diagnosis. Medical genetics is increasingly becoming relevant to many common diseases. Overlaps with other medical specialties are beginning to emerge, as recent advances in genetics are revealing etiologies for neurologic, endocrine, cardiovascular, pulmonary, ophthalmologic, renal, psychiatric, and dermatologic conditions.

In some ways, many of the individual fields within medical genetics are hybrids between clinical care and research. This is due in part to recent advances in science and technology (for example, see the Human genome project) that have enabled an unprecedented understanding of genetic disorders.

Clinical genetics is the practice of clinical medicine with particular attention to hereditary disorders. Referrals are made to genetics clinics for a variety of reasons, including birth defects, developmental delay, autism, epilepsy, short stature, and many others. Examples of genetic syndromes that are commonly seen in the genetics clinic include chromosomal rearrangements, Down syndrome, DiGeorge syndrome (22q11.2 Deletion Syndrome), Fragile X syndrome, Marfan syndrome, Neurofibromatosis, Turner syndrome, and Williams syndrome.

In the United States, physicians who practice clinical genetics are accredited by the American Board of Medical Genetics and Genomics (ABMGG).[1] In order to become a board-certified practitioner of Clinical Genetics, a physician must complete a minimum of 24 months of training in a program accredited by the ABMGG. Individuals seeking acceptance into clinical genetics training programs must hold an M.D. or D.O. degree (or their equivalent) and have completed a minimum of 24 months of training in an ACGME-accredited residency program in internal medicine, pediatrics, obstetrics and gynecology, or other medical specialty.[2]

Metabolic (or biochemical) genetics involves the diagnosis and management of inborn errors of metabolism in which patients have enzymatic deficiencies that perturb biochemical pathways involved in metabolism of carbohydrates, amino acids, and lipids. Examples of metabolic disorders include galactosemia, glycogen storage disease, lysosomal storage disorders, metabolic acidosis, peroxisomal disorders, phenylketonuria, and urea cycle disorders.

Cytogenetics is the study of chromosomes and chromosome abnormalities. While cytogenetics historically relied on microscopy to analyze chromosomes, new molecular technologies such as array comparative genomic hybridization are now becoming widely used. Examples of chromosome abnormalities include aneuploidy, chromosomal rearrangements, and genomic deletion/duplication disorders.

Molecular genetics involves the discovery of and laboratory testing for DNA mutations that underlie many single gene disorders. Examples of single gene disorders include achondroplasia, cystic fibrosis, Duchenne muscular dystrophy, hereditary breast cancer (BRCA1/2), Huntington disease, Marfan syndrome, Noonan syndrome, and Rett syndrome. Molecular tests are also used in the diagnosis of syndromes involving epigenetic abnormalities, such as Angelman syndrome, Beckwith-Wiedemann syndrome, Prader-willi syndrome, and uniparental disomy.

Mitochondrial genetics concerns the diagnosis and management of mitochondrial disorders, which have a molecular basis but often result in biochemical abnormalities due to deficient energy production.

There exists some overlap between medical genetic diagnostic laboratories and molecular pathology.

Genetic counseling is the process of providing information about genetic conditions, diagnostic testing, and risks in other family members, within the framework of nondirective counseling. Genetic counselors are non-physician members of the medical genetics team who specialize in family risk assessment and counseling of patients regarding genetic disorders. The precise role of the genetic counselor varies somewhat depending on the disorder.

Although genetics has its roots back in the 19th century with the work of the Bohemian monk Gregor Mendel and other pioneering scientists, human genetics emerged later. It started to develop, albeit slowly, during the first half of the 20th century. Mendelian (single-gene) inheritance was studied in a number of important disorders such as albinism, brachydactyly (short fingers and toes), and hemophilia. Mathematical approaches were also devised and applied to human genetics. Population genetics was created.

Medical genetics was a late developer, emerging largely after the close of World War II (1945) when the eugenics movement had fallen into disrepute. The Nazi misuse of eugenics sounded its death knell. Shorn of eugenics, a scientific approach could be used and was applied to human and medical genetics. Medical genetics saw an increasingly rapid rise in the second half of the 20th century and continues in the 21st century.

The clinical setting in which patients are evaluated determines the scope of practice, diagnostic, and therapeutic interventions. For the purposes of general discussion, the typical encounters between patients and genetic practitioners may involve:

Each patient will undergo a diagnostic evaluation tailored to their own particular presenting signs and symptoms. The geneticist will establish a differential diagnosis and recommend appropriate testing. Increasingly, clinicians use SimulConsult, paired with the National Library of Medicine Gene Review articles, to narrow the list of hypotheses (known as the differential diagnosis) and identify the tests that are relevant for a particular patient. These tests might evaluate for chromosomal disorders, inborn errors of metabolism, or single gene disorders.

Chromosome studies are used in the general genetics clinic to determine a cause for developmental delay/mental retardation, birth defects, dysmorphic features, and/or autism. Chromosome analysis is also performed in the prenatal setting to determine whether a fetus is affected with aneuploidy or other chromosome rearrangements. Finally, chromosome abnormalities are often detected in cancer samples. A large number of different methods have been developed for chromosome analysis:

Biochemical studies are performed to screen for imbalances of metabolites in the bodily fluid, usually the blood (plasma/serum) or urine, but also in cerebrospinal fluid (CSF). Specific tests of enzyme function (either in leukocytes, skin fibroblasts, liver, or muscle) are also employed under certain circumstances. In the US, the newborn screen incorporates biochemical tests to screen for treatable conditions such as galactosemia and phenylketonuria (PKU). Patients suspected to have a metabolic condition might undergo the following tests:

Each cell of the body contains the hereditary information (DNA) wrapped up in structures called chromosomes. Since genetic syndromes are typically the result of alterations of the chromosomes or genes, there is no treatment currently available that can correct the genetic alterations in every cell of the body. Therefore, there is currently no "cure" for genetic disorders. However, for many genetic syndromes there is treatment available to manage the symptoms. In some cases, particularly inborn errors of metabolism, the mechanism of disease is well understood and offers the potential for dietary and medical management to prevent or reduce the long-term complications. In other cases, infusion therapy is used to replace the missing enzyme. Current research is actively seeking to use gene therapy or other new medications to treat specific genetic disorders.

In general, metabolic disorders arise from enzyme deficiencies that disrupt normal metabolic pathways. For instance, in the hypothetical example:

Compound "A" is metabolized to "B" by enzyme "X", compound "B" is metabolized to "C" by enzyme "Y", and compound "C" is metabolized to "D" by enzyme "Z". If enzyme "Z" is missing, compound "D" will be missing, while compounds "A", "B", and "C" will build up. The pathogenesis of this particular condition could result from lack of compound "D", if it is critical for some cellular function, or from toxicity due to excess "A", "B", and/or "C". Treatment of the metabolic disorder could be achieved through dietary supplementation of compound "D" and dietary restriction of compounds "A", "B", and/or "C" or by treatment with a medication that promoted disposal of excess "A", "B", or "C". Another approach that can be taken is enzyme replacement therapy, in which a patient is given an infusion of the missing enzyme.

Dietary restriction and supplementation are key measures taken in several well-known metabolic disorders, including galactosemia, phenylketonuria (PKU), maple syrup urine disease, organic acidurias and urea cycle disorders. Such restrictive diets can be difficult for the patient and family to maintain, and require close consultation with a nutritionist who has special experience in metabolic disorders. The composition of the diet will change depending on the caloric needs of the growing child and special attention is needed during a pregnancy if a woman is affected with one of these disorders.

Medical approaches include enhancement of residual enzyme activity (in cases where the enzyme is made but is not functioning properly), inhibition of other enzymes in the biochemical pathway to prevent buildup of a toxic compound, or diversion of a toxic compound to another form that can be excreted. Examples include the use of high doses of pyridoxine (vitamin B6) in some patients with homocystinuria to boost the activity of the residual cystathione synthase enzyme, administration of biotin to restore activity of several enzymes affected by deficiency of biotinidase, treatment with NTBC in Tyrosinemia to inhibit the production of succinylacetone which causes liver toxicity, and the use of sodium benzoate to decrease ammonia build-up in urea cycle disorders.

Certain lysosomal storage diseases are treated with infusions of a recombinant enzyme (produced in a laboratory), which can reduce the accumulation of the compounds in various tissues. Examples include Gaucher disease, Fabry disease, Mucopolysaccharidoses and Glycogen storage disease type II. Such treatments are limited by the ability of the enzyme to reach the affected areas (the blood brain barrier prevents enzyme from reaching the brain, for example), and can sometimes be associated with allergic reactions. The long-term clinical effectiveness of enzyme replacement therapies vary widely among different disorders.

There are a variety of career paths within the field of medical genetics, and naturally the training required for each area differs considerably. It should be noted that the information included in this section applies to the typical pathways in the United States and there may be differences in other countries. US Practitioners in clinical, counseling, or diagnostic subspecialties generally obtain board certification through the American Board of Medical Genetics.

Genetic information provides a unique type of knowledge about an individual and his/her family, fundamentally different from a typically laboratory test that provides a "snapshot" of an individual's health status. The unique status of genetic information and inherited disease has a number of ramifications with regard to ethical, legal, and societal concerns.

On 19 March 2015, scientists urged a worldwide ban on clinical use of methods, particularly the use of CRISPR and zinc finger, to edit the human genome in a way that can be inherited.[3][4][5][6] In April 2015 and April 2016, Chinese researchers reported results of basic research to edit the DNA of non-viable human embryos using CRISPR.[7][8][9] In February 2016, British scientists were given permission by regulators to genetically modify human embryos by using CRISPR and related techniques on condition that the embryos were destroyed within seven days.[10] In June 2016 the Dutch government was reported to be planning to follow suit with similar regulations which would specify a 14-day limit.[11]

The more empirical approach to human and medical genetics was formalized by the founding in 1948 of the American Society of Human Genetics. The Society first began annual meetings that year (1948) and its international counterpart, the International Congress of Human Genetics, has met every 5 years since its inception in 1956. The Society publishes the American Journal of Human Genetics on a monthly basis.

Medical genetics is now recognized as a distinct medical specialty in the U.S. with its own approved board (the American Board of Medical Genetics) and clinical specialty college (the American College of Medical Genetics). The College holds an annual scientific meeting, publishes a monthly journal, Genetics in Medicine, and issues position papers and clinical practice guidelines on a variety of topics relevant to human genetics.

The broad range of research in medical genetics reflects the overall scope of this field, including basic research on genetic inheritance and the human genome, mechanisms of genetic and metabolic disorders, translational research on new treatment modalities, and the impact of genetic testing

Basic research geneticists usually undertake research in universities, biotechnology firms and research institutes.

Sometimes the link between a disease and an unusual gene variant is more subtle. The genetic architecture of common diseases is an important factor in determining the extent to which patterns of genetic variation influence group differences in health outcomes.[12][13][14] According to the common disease/common variant hypothesis, common variants present in the ancestral population before the dispersal of modern humans from Africa play an important role in human diseases.[15] Genetic variants associated with Alzheimer disease, deep venous thrombosis, Crohn disease, and type 2 diabetes appear to adhere to this model.[16] However, the generality of the model has not yet been established and, in some cases, is in doubt.[13][17][18] Some diseases, such as many common cancers, appear not to be well described by the common disease/common variant model.[19]

Another possibility is that common diseases arise in part through the action of combinations of variants that are individually rare.[20][21] Most of the disease-associated alleles discovered to date have been rare, and rare variants are more likely than common variants to be differentially distributed among groups distinguished by ancestry.[19][22] However, groups could harbor different, though perhaps overlapping, sets of rare variants, which would reduce contrasts between groups in the incidence of the disease.

The number of variants contributing to a disease and the interactions among those variants also could influence the distribution of diseases among groups. The difficulty that has been encountered in finding contributory alleles for complex diseases and in replicating positive associations suggests that many complex diseases involve numerous variants rather than a moderate number of alleles, and the influence of any given variant may depend in critical ways on the genetic and environmental background.[17][23][24][25] If many alleles are required to increase susceptibility to a disease, the odds are low that the necessary combination of alleles would become concentrated in a particular group purely through drift.[26]

One area in which population categories can be important considerations in genetics research is in controlling for confounding between population substructure, environmental exposures, and health outcomes. Association studies can produce spurious results if cases and controls have differing allele frequencies for genes that are not related to the disease being studied,[27] although the magnitude of this problem in genetic association studies is subject to debate.[28][29] Various methods have been developed to detect and account for population substructure,[30][31] but these methods can be difficult to apply in practice.[32]

Population substructure also can be used to advantage in genetic association studies. For example, populations that represent recent mixtures of geographically separated ancestral groups can exhibit longer-range linkage disequilibrium between susceptibility alleles and genetic markers than is the case for other populations.[33][34][35][36] Genetic studies can use this admixture linkage disequilibrium to search for disease alleles with fewer markers than would be needed otherwise. Association studies also can take advantage of the contrasting experiences of racial or ethnic groups, including migrant groups, to search for interactions between particular alleles and environmental factors that might influence health.[37][38]

Read the original:
Medical genetics - Wikipedia

Posted in Gene Medicine | Comments Off on Medical genetics – Wikipedia

Page 2,115«..1020..2,1142,1152,1162,117..2,1202,130..»